_ Beijing: Six drugs, including nimativir tablets and ritonavir tablets, are temporarily included in medical insurance.
In order to cope with the new epidemic situation, with the approval of the National Medical Insurance Bureau, Beijing Medical Insurance Bureau temporarily included six drugs, such as compound paracetamol capsules, compound paracetamol and ephedrine oral liquid, paracetamol for children, Anka Huang Min capsules, clofenHuang Min tablets and ambroxol oral liquid, into the scope of medical insurance and industrial injury insurance reimbursement in Beijing, and the reimbursement ratio was implemented according to Class A drugs. It will be implemented from 12 to 18 in 2022 and will be valid until March 2023 18.
In addition, in order to strengthen the treatment of patients who may develop into severe or critical illness after COVID-19's infection, recently, Naimavir Tablets/Ritonavir Tablets have also been included in the scope of medical insurance drug reimbursement in Beijing, and the reimbursement rate of community hospitals in Beijing is 90%.
_ Guangdong: Internet first diagnosis antigen testing, Guangdong medical insurance gives policy support.
The reporter learned from Guangdong Medical Insurance Bureau that Guangdong issued a policy on February 20, 2022, and 65438+2022 supported the medical expenses generated by the first clinic of the insured patient "internet plus" to be included in the scope of medical insurance payment in Guangdong Province, and at the same time increased the support for COVID-19 antigen testing.
From June, 5438 to February, 2022, the Provincial Medical Insurance Bureau issued the Notice on Further Improving the Medical Insurance Payment for internet plus medical services in COVID-19. The insured shall make the first visit in the designated medical institutions of internet plus (including Internet hospitals and medical institutions providing Internet diagnosis and treatment services), and the medical examination fee and medicine fee shall meet the requirements, and the basic medical insurance fund shall pay them according to the provisions. However, the cost of drug distribution service is not included in the scope of medical insurance payment.
According to the deployment of National Medical Insurance Bureau, novel coronavirus antigen detection reagents and corresponding detection items have been temporarily included in the catalogue of medical consumables and diagnosis and treatment items in Guangdong Province. The cost of COVID-19 antigen testing for insured patients in primary medical institutions shall be paid by the medical insurance fund according to regulations. In addition, the expenses for the insured person to purchase COVID-19 antigen detection reagents in designated retail pharmacies can be paid by using the employee medical insurance personal account. Spouses, parents and children of the insured can use the personal account of the insured to purchase antigen detection reagents in designated medical institutions.
_ Hubei: 36 kinds of COVID-19 drugs are temporarily included in medical insurance.
Hubei Provincial Medical Insurance Bureau reported on February 29, 2022 that with the approval of the National Medical Insurance Bureau, 36 kinds of COVID-19 drugs, such as paracetamol for children and compound pholcodine syrup, were temporarily included in the scope of medical insurance reimbursement in Hubei Province from February 29, 2022, and the reimbursement ratio was implemented according to Class A drugs.
_ Anhui: The reimbursement rate of outpatient expenses for infection in COVID-19 is 70%.
According to the news of Anhui Medical Insurance Bureau, it is clear that the insured COVID-19's medical expenses, which meet the requirements of COVID-19's infection diagnosis and treatment plan, are included in the payment scope of the basic medical insurance pooling fund, with no deductible line and reimbursement limit, and the reimbursement ratio is 70%.
_ Shandong: Online consultation on symptoms in COVID-19 is included in medical insurance reimbursement.
According to the website of Shandong Provincial Medical Insurance Bureau on February 28th, 2022, Shandong Provincial Medical Insurance Bureau and Shandong Provincial Health and Wellness Committee recently jointly issued the Notice on Doing a Good Job in Medical Insurance Services for Internet Infection in novel coronavirus, pointing out that the Internet diagnosis fee for related symptoms in COVID-19 should be included in the basic medical insurance payment scope, which is consistent with the offline reimbursement policy.
_ Shaanxi: 234 kinds of COVID-19 drugs are temporarily included in medical insurance.
According to the news of "Healthy Shaanxi Release" on February 22, 2022, Shaanxi Provincial Medical and Social Security Bureau and other three units jointly issued a notice. The confirmed and suspected patients will use 107 kinds of Chinese patent medicines recommended in the Notice of Shaanxi Provincial Health and Wellness Committee and Shaanxi Provincial Administration of Traditional Chinese Medicine on Printing and Distributing the Prevention and Treatment Scheme of Infection in Shaanxi Province (Trial Fourth Edition) (No.53 [2022] of Shaanxi Traditional Chinese Medicine) and two kinds of 65438 selected by experts organized by the provincial and provincial health and wellness committees, which have strong pertinence to the disease and obvious therapeutic effect.
_ Yunnan: 4 1 Drugs are temporarily included in medical insurance.
Yunnan Provincial Medical Security Bureau reported in 65438 on February 30th, 2022 that 4 1 drugs such as "Sangju Yinqiao Powder" in the Catalogue of Drugs for Infected Persons in COVID-19, Yunnan Province (First Edition for Trial Implementation) were temporarily included in the scope of medical insurance payment, and they were managed according to Class A drugs, so as to further meet people's medical needs and reduce the cost burden of infected persons in COVID-19.
_ Guangxi: 15 kinds of COVID-19 drugs can be used for medical insurance.
According to Guangxi News Network, in order to further protect the people's demand for drugs, the Medical Security Bureau of the Autonomous Region temporarily included 15 kinds of drugs such as exogenous fever granules into the payment scope of the basic medical insurance fund of the whole region, and reimbursed them according to Class A drugs of medical insurance, which was implemented from February 22, 2022 to March 22, 2023.
More news
The latest judgment of Academician Chen Saijuan's team;
Around New Year's Day, the epidemic situation in many places is coming to an end.
Chen Saijuan, an academician of China Academy of Sciences, said that among the people who have recently developed symptoms of COVID-19 infection, severe cases are mainly concentrated in the elderly with basic diseases; The Spring Festival is coming, and rural areas with relatively weak medical resources need close attention.
Academician of China Academy of Sciences, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Chen Saijuan team of State Key Infrastructure of Translational Medicine (Shanghai) and Fan Xiaohong team of Shanghai Public Health Clinical Center jointly tackled key problems, and published a research paper "Preliminary Analysis of Omicron Subtype Diversity and Epidemiological Characteristics of COVID-19 Epidemic in Autumn and Winter in China in 2022" in Medical Frontier magazine. According to the preliminary judgment of the researchers, the number of people infected with Omicron in Beijing, Guangzhou, Shanghai, Chongqing and other cities will come to an end around New Year's Day in 2023.